Autism researchers worldwide could use the mouse model to study ways to compensate for the gene and improve symptoms in people with autism spectrum disorders and Phelan-McDermid Syndrome

Researchers are developing quick ways to convert information into lead drugs by using several novel and transformative technologies they've developed

A protein called Musashi-2 regulates the function and development of important blood stem cells

University of Saskatchewan researchers will share a total of $844,000 from the Canada Foundation for Innovation (CFI) for wide-ranging projects that will explore potential health benefits of using pulse crops in pet and fish feeds, energy-efficient technology for removing water from biofuels, catalysts to clean up air and water, and genetic and environmental factors underlying diseases such as cancer and osteoarthritis.

Niche Diagnostics Center of Excellence develops and manufactures products used worldwide in healthcare and other markets.

In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.

Thermo Fisher Scientific has developed a high-resolution hydrophobic interaction chromatography (HIC) method that can separate a fusion protein from a truncated version and a structural isomer.

For years, researchers and patients have hoped that embryonic stem cells (ESCs)—capable of forming nearly any cell type in the body—could provide insight into numerous diseases perhaps even be used to treat them. Yet progress has been hampered by the inability to transfer research and tools from mouse ESC studies to their human counterparts, in part because human ESCs are “primed” and slightly less plastic than the mouse cells.

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.

NYU Langone Medical Center has established a new drug discovery accelerator, the Office of Therapeutics Alliances (OTA). OTA is an innovative, nimble program that advances the discovery of novel therapeutic projects by combining the scientific strengths of NYU Langone investigators in dissecting disease pathways with the expertise of external professional drug discovery and development partners in the biopharma industry.